A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
The main purpose of this study is to evaluate the safety and efficacy of the combination therapy of ramucirumab and nivolumab in participants with advanced or recurrent unresectable gastric or GEJ cancer.
Gastric Cancer|Gastroesophageal Junction Region (GEJ) Cancer
BIOLOGICAL: Ramucirumab|BIOLOGICAL: Nivolumab
Number of participants with dose limiting toxicities (DLTs), Number of participants with dose limiting toxicities (DLTs), Phase 1, course 1 (up to 28 days)|Progression free survival rate after 6 months, Progression free survival rate after 6 months, from baseline to 6 months
Number of participants with adverse events, Number of participants with adverse events, from baseline to date of treatment cessation, approximately 24 months|Objective response rate (ORR), percentage of participants with with a best response of complete response (CR) or partial response (PR), from baseline to date of disease progression, approximately 24 months|Disease control rate (DCR), percentage of participants with with a best response of CR, PR or stable disease (SD), from baseline to date of disease progression, approximately 24 months|Overall survival (OS), Overall survival (OS), from baseline to date of death, approximately 24 months|Progression free survival (PFS), Progression free survival (PFS), from baseline to date of disease progression or death, approximately 24 months
The main purpose of this study is to evaluate the safety and efficacy of the combination therapy of ramucirumab and nivolumab in participants with advanced or recurrent unresectable gastric or GEJ cancer.